Get the Stockscreener App
16.97
1.85%
-0.32
After Hours:
16.97
Spyre Therapeutics Inc stock is traded at $16.97, with a volume of 599.80K.
It is down -1.85% in the last 24 hours and up +13.36% over the past month.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$17.29
Open:
$17.1
24h Volume:
599.80K
Relative Volume:
1.08
Market Cap:
$1.02B
Revenue:
$1.23M
Net Income/Loss:
$-214.90M
P/E Ratio:
-4.1167
EPS:
-4.1222
Net Cash Flow:
$-151.25M
1W Performance:
-3.58%
1M Performance:
+13.36%
6M Performance:
-26.19%
1Y Performance:
-38.29%
1-Day Range:
$16.57
$17.32
1-Week Range:
$16.43
$18.00
52-Week Range:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
16.97 | 1.04B | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
What moving averages say about Spyre Therapeutics Inc.Weekly Outlook for Short Term Investors - Newser
Visual trend scoring systems applied to Spyre Therapeutics Inc.Algorithmic Forecast for Swing Trading Picks - Newser
How strong is Spyre Therapeutics Inc. company’s balance sheetAI Powered Forecasts With Proven Results - jammulinksnews.com
What catalysts could drive Spyre Therapeutics Inc. stock higher in 2025Free Stock Watchlist For Fast Growth - jammulinksnews.com
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionFree Access to Real-Time Trade Insights - Newser
Will a bounce in Spyre Therapeutics Inc. offer an exitFree Community Shared Smart Money Signals - Newser
What is the dividend policy of Spyre Therapeutics Inc. stockWealth Building Trend Scanner For 2025 - jammulinksnews.com
Can momentum traders help lift Spyre Therapeutics Inc.Short-Term Bounce Forecast for Oversold Stocks - Newser
How hedge fund analytics apply to Spyre Therapeutics Inc. stockAI Screener Based Stock Summary Report - Newser
Spyre Therapeutics Inc. stock trend outlook and recovery pathBuy Signal System Based on Price Action - Newser
How to track smart money flows in Spyre Therapeutics Inc.Buy Signal System Based on Price Action - Newser
Identifying reversal signals in Spyre Therapeutics Inc.High Reward Investment Strategy for Beginners - Newser
Moving Average Trends for Spyre Therapeutics Inc. Stock: What They IndicateDaily Market Momentum Summary and Strategy - Newser
Sector ETF Data Correlates with Strength in Spyre Therapeutics Inc.Intraday Trend Analysis for Fast Gains Released - metal.it
Trading Bots Trigger Alerts on Spyre Therapeutics Inc. ActivityCapital Growth With Controlled Risk Picks Suggested - metal.it
How Resilient Is Spyre Therapeutics Inc. Stock During Economic DownturnsChart Breakout Buy Signal Detection Confirmed - metal.it
Published on: 2025-07-29 08:11:08 - metal.it
What are the technical indicators suggesting about Spyre Therapeutics Inc.Post Market Opportunities For Consistent Profits - jammulinksnews.com
How does Spyre Therapeutics Inc. compare to its industry peersSwing Trade Target Finder With Low Risk - jammulinksnews.com
Published on: 2025-07-28 20:59:32 - metal.it
How volatile is Spyre Therapeutics Inc. stock compared to the marketBreakout Stocks Tracker With High Returns - jammulinksnews.com
Published on: 2025-07-28 18:29:12 - metal.it
Market reaction to Spyre Therapeutics Inc.’s recent newsConservative Asset Allocation Risk Analysis - Newser
Victory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
How Resilient Is Spyre Therapeutics Inc. Stock During Economic Downturns AI Trading Forecast Based on Big Data - Newser
Market reaction to Spyre Therapeutics Inc.’s recent news Free Quick Gain Stock Watch With Indicators - metal.it
What makes Spyre Therapeutics Inc. stock price move sharplyExplosive portfolio gains - jammulinksnews.com
Will Spyre Therapeutics Inc. stock benefit from AI tech trendsTremendous financial leverage - jammulinksnews.com
Is Spyre Therapeutics Inc. a good long term investmentHigh-impact stock picks - PrintWeekIndia
Spyre Therapeutics Inc. Stock Analysis and ForecastFree Investment Risk Control - PrintWeekIndia
What analysts say about Spyre Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
This Spyre Therapeutics Insider Reduced Their Stake By 55% - 富途牛牛
What drives Spyre Therapeutics Inc. stock priceRapid capital growth - jammulinksnews.com
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):